Literature DB >> 16045774

Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

R Ryan1, D Gibbons, J M P Hyland, D Treanor, A White, H E Mulcahy, D P O'Donoghue, M Moriarty, D Fennelly, K Sheahan.   

Abstract

AIMS: To standardize the pathological analysis of total mesorectal excision specimens of rectal cancer following neoadjuvant chemoradiotherapy for locally advanced disease (T3/T4), including tumour regression. METHODS AND
RESULTS: Standardized dissection and reporting was used for 60 patients who underwent total mesorectal excision following long-course chemoradiotherapy. Tumour regression was scored by two pathologists (K.S., D.G.) using both an established 5-point tumour regression grade (TRG), and a novel 3-point grade. Both scores were evaluated for interobserver variability. A complete or near-complete pathological response (3-point TRG 1) was found in 10 patients (17%). Using the 5-point TRG, there was good agreement between both pathologists (kappa = 0.64). Using the 3-point grade, agreement was excellent (kappa = 0.84). No disease recurrence has been reported in patients with a complete, or near complete pathological response (3-point TRG 1), after a mean follow-up of 22 months.
CONCLUSION: Tumour regression grade is a useful method of scoring tumour response to chemoradiotherapy in rectal cancer. TRG 1 and 2 can be regarded as a complete pathological response (ypT0). A modified 3-point grade has the advantage of better reproducibility, with similar prognostic significance.

Entities:  

Mesh:

Year:  2005        PMID: 16045774     DOI: 10.1111/j.1365-2559.2005.02176.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  170 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  [Pathological staging and response evaluation of rectal carcinoma].

Authors:  C Wittekind; B Oberschmid
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

3.  Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study.

Authors:  Farrokh Dehdashti; Perry W Grigsby; Robert J Myerson; Ilke Nalbantoglu; Changqing Ma; Barry A Siegel
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

4.  Invited commentary on "Yun HR, Kim HC, Kim SH et al. (2010) Cytokeratin staining for complete remission in rectal cancer after chemoradiation. Int J Colorect Dis.

Authors:  Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2010-06-09       Impact factor: 2.571

5.  Recommendations for the reporting of surgically resected specimens of colorectal carcinoma.

Authors:  Jeremy R Jass; Michael J O'Brien; Robert H Riddell; Dale C Snover
Journal:  Virchows Arch       Date:  2006-11-25       Impact factor: 4.064

6.  Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.

Authors:  Dan Jiang; Xin Wang; Yajian Wang; Dana Philips; Wenjian Meng; Moli Xiong; Junyi Zhao; Linyong Sun; Du He; Kun Li
Journal:  Virchows Arch       Date:  2019-05-06       Impact factor: 4.064

7.  Machine learning for prediction of chemoradiation therapy response in rectal cancer using pre-treatment and mid-radiation multi-parametric MRI.

Authors:  Liming Shi; Yang Zhang; Ke Nie; Xiaonan Sun; Tianye Niu; Ning Yue; Tiffany Kwong; Peter Chang; Daniel Chow; Jeon-Hor Chen; Min-Ying Su
Journal:  Magn Reson Imaging       Date:  2019-05-03       Impact factor: 2.546

8.  Tumor deposits in rectal adenocarcinoma after neoadjuvant chemoradiation are associated with poor prognosis.

Authors:  Purva Gopal; Pengcheng Lu; Gregory D Ayers; Alan J Herline; Mary K Washington
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

9.  Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.

Authors:  Hiroyuki Kodama; Tetsuji Terazawa; Yasunobu Ishizuka; Hiroki Yukami; Masahiko Aoki; Takahiro Miyamoto; Toshifumi Yamaguchi; Futukaro Shimamoto; Takayuki Kii; Masahiro Goto; Hiroki Hamamoto; Wataru Osumi; Masashi Yamamoto; Keitaro Tanaka; Jyunji Okuda; Kazuhisa Uchiyama; Kazuhide Higuchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  The pathologist's role in rectal cancer patient assessments.

Authors:  Joseph E Willis
Journal:  Clin Colon Rectal Surg       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.